Biotech and Pharmaceuticals Pharmaceuticals

More

  • Arthur Levinson

    I've been trying for years to get an interview with Genentech CEO Art Levinson. As far as I know, he's never done a TV chat. Every time I've asked the answer has come back no. I've gotten pretty good access to other execs, but never the top dog.

  • roche_genentech.jpg

    Shares of Swiss drugmaker Roche are trading significantly lower overseas and in over-the-counter activity here in the States after the company reported earnings.

  • FDA

    Right around the closing bell today an FDA advisory committee voted unanimously in favor of recommending approval of Eli Lilly's bloodthinner called Effient.

  • Gardasil

    Before Gardasil came to market two to three years ago, some analysts were saying it would become the biggest-selling vaccine in history. But hope and reality have turned out to be two different things.

  • If so, that could mean big bucks for this pharmacy-benefits manager.

  • Amylin

    Diabetes drugmaker Amylin Pharmaceuticals is headquartered in San Diego. Like a lot of companies, though, it's incorporated in Delaware. But, if a couple of major shareholders get their way, AMLN could reincorporate in an unlikely state.

  • So, what do you do at the end of a week where your company's stock was the worst performer in the Dow and you've got some bad news that could make the shares go down even more? You employ one of the oldest PR tricks in the book.

  • Genentech shares dropped three percent today or $2.85 to $81.24 after Roche showed some chutzpah and lowered its bid for DNA. 

  • That’s the possible result after today's shocking DNA test.

  • chantix_ad4.jpg

    Pfizer is quitting the ad agency that tried to tell smokers it's their time to quit.

  • Sequenom

    I need a break from blogging all-things Pfizer. Sequenom to the rescue with more data on its diagnostic test for Down Syndrome. Out of nearly 900 women there were no false negatives, but for the first time SQNM reported one false positive.

  • lilly_hq.jpg

    Drugmaker Eli Lilly said Thursday it swung to a loss in the fourth quarter on charges from buying cancer-drug maker ImClone Systems.

  • The editorial board of "The Wall Street Journal" weighs in today on the Pfizer-Wyeth deal. The opinion piece details all of the well-documented problems facing big pharma and—perhaps not surprisingly coming from the WSJ editorial page—blames Washington for many of them.

  • pfizer_hq.jpg

    Reporters could only listen to Pfizer's hastily-organized "Investor Luncheon," so I can't tell you how many people showed up or what the room looked like. But Chairman and CEO Jeff Kindler drew a pretty good picture at the start of his opening remarks.

  • pfizer_wyet_ad.jpg

    This is the first paragraph/short story.

  • Major indexes finished higher after a yo-yo session Monday, with banks ending mixed after several attempts at a rally.

  • Stocks rallied, led by banks, after a wobbly open Monday. The market also got a boost from a blockbuster pharma deal, which helped overshadow a gloomy outlook from Caterpillar and other earnings worries.

  • Pfizer & Wyeth

    As I've blogged before, it seems all of the major drug companies are falling all over each other to be the biggest, or at least the best "biopharma" firm in the world. But PFE and WYE are the first, as far as I know, to put it into a URL.

  • Stocks got a boost from a better-than-expected report on the housing market, which overshadowed Caterpillar's gloomy outlook and other earnings worries.

  • Stock index futures pointed to a dip at the opening, despite a mega-deal brewing in the pharmaceutical sector.